Clinical trials: Viral Hepatitis
Hepatitis B, Decompensated Cirrhosis
Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis
In this study, treatment-naïve HBV-related cirrhosis patients were retrospectively enrolled at the first episode of decompensation (ascites or variceal hemorrhage).
- Trial name
- NCT05086536
- Testing
- no intervention
- Where
- 7 sites in China
- Volunteers
- 600 people
- Sponsor
- Beijing Friendship Hospital
Hepatitis C Virus Infection
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection
The primary objectives of this study are to determine the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in adults with chronic genotype 1 or 2 HCV infection who are…
- Trial name
- NCT02613871
- Testing
- LDV/SOF
- Where
- 8 sites in Taiwan
- Volunteers
- 111 people
- Sponsor
- Gilead Sciences
Hepatitis C, Liver Transplantation
Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients
This is an exploratory study to evaluate the impact of eliminating steroid administration upon viral HCV load at 12 months measured by quantitative serum HCV-RNA determination in patients transplanted for HCV cirrhosis.
- Trial name
- CHASE (NCT00295607)
- Testing
- Tacrolimus, steroids, monoclonal anti-IL2R antibody
- Where
- 17 sites in Czechia, France and 6 more
- Volunteers
- 138 people
- Sponsor
- Astellas Pharma Inc
Hepatitis B, Liver Transplantation
HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection
The purpose of this study is to compare the use of HepeX-B versus HBIg, two anti-viral drugs, in patients who have received liver transplants due to liver failure caused by Hepatitis B infection.
- Trial name
- NCT00228592
- Testing
- HepeX-B, Hepatitis B Immune Globulin (HBIg)
- Where
- 20 sites in United States, France and 5 more
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Hepatitis C, Liver Fibrosis
Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)
The objective of the study is to evaluate the safety and efficacy of PEG-Intron versus no treatment for the prevention of fibrosis progression in adult participants with moderate to severe liver fibrosis secondary to chronic…
- Trial name
- NCT00049842
- Testing
- peginterferon alfa-2b (SCH 54031)
- Volunteers
- 540 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis B
An Study of Efficacy and Safety of Clevudine
Randomized, double blind parallel group, positive control, multi-center trial. Patients will be randomized at 1:1 ratio in group A or group B
- Trial name
- NCT01192854
- Testing
- Clevudine, Adefovir
- Where
- China
- Volunteers
- 288 people
- Sponsor
- Eisai Co., Ltd.
Hepatitis C, Hepatic Steatosis
Oxidative Stress and Fatty Acids in Hepatitis C
Hepatitis C virus infection (HCV) is a major health concern in Canada and worldwide. Chronic HCV can cause progressive liver damage leading to inflammation, scarring and, in some cases, cirrhosis or liver cancer.
- Trial name
- NCT00444002
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Johane Allard
Hepatitis C Virus Infection
Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir (SOF)/velpatasvir (VEL; GS-5816) fixed-dose combination (FDC) for 12 weeks in participants with chronic…
- Trial name
- NCT02671500
- Testing
- SOF/VEL
- Where
- 38 sites in China, Malaysia and 3 more
- Volunteers
- 375 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
Nabi-HB Administered Subcutaneously in Patients With Hepatitis B Virus Post Liver Transplantation
A phase 3, multicenter, open label study to assess the safety and efficacy of Nabi-HB, administered subcutaneously in patients with Hepatitis B Virus Associated Liver Disease who underwent liver transplantation.
- Trial name
- Nabi-HB-SC (NCT00800787)
- Testing
- Nabi-HB
- Sponsor
- Biotest Pharmaceuticals Corporation
Hepatitis C Virus
A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir
The purpose of this study is to evaluate the effectiveness of a simeprevir-containing hepatitis C virus (HCV) treatment regimen as measured by sustained virologic response (SVR).
- Trial name
- NCT02103699
- Testing
- No intervention
- Where
- 32 sites in United States
- Volunteers
- 315 people
- Sponsor
- Janssen Scientific Affairs, LLC
Hepatitis B, Chronic
A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
The purpose of this study is to evaluate the efficacy in terms of hepatitis B surface antigen (HBsAg) levels of the study intervention (that is, JNJ-73763989 + JNJ-56136379 + nucleos[t]ide analog [NA] and pegylated interferon…
- Trial name
- PENGUIN (NCT04667104)
- Testing
- JNJ-73763989, Tenofovir disoproxil, Tenofovir alafenamide (TAF)
- Where
- 11 sites in Japan, New Zealand and 2 more
- Volunteers
- 48 people
- Sponsor
- Janssen Research & Development, LLC
HIV Infections, Hepatitis C
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy
The purpose of this study is to evaluate if the combination of Lpv/r monotherapy and anti-HCV drugs does not match with additional toxicity induced by the association of HAART and Peg-IFN + ritonavir in HIV/HCV coinfected…
- Trial name
- NCT00437684
- Testing
- LPV/r, PEG-IFNa 2a, Ribavirin
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
HCV Infection
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
The primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of voxilaprevir (formerly GS-9857) in participants with severe renal impairment and matched healthy control participants.
- Trial name
- NCT02402452
- Testing
- Voxilaprevir
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hepatitis C, Cirrhosis
Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis
Direct-acting antiviral agents (DAAs) targeting HCV have revolutionized the treatment of HCV. The efficacy of DAA-based therapy can depend on patient-related factors such as treatment experience, cirrhosis, but also on viral…
- Trial name
- NCT05467826
- Testing
- Sofosbuvir/Velpatasvir + Ribavirin, Sofosbuvir/Velpatasvir/Voxilaprevir
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Hepatitis C
Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing
This non-interventional clinical study will be conducted to prospectively collect serial plasma and serum samples from treatment naïve subjects with chronic HCV infection who are initiating sofosbuvir-based therapy.
- Trial name
- NCT02068963
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 352 people
- Sponsor
- Hologic, Inc.
Diphtheria, Tetanus
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants
This study will assess both the antibody persistence of the investigational vaccine and the immune response and safety of a booster dose of PENTAXIM™ vaccine in 18 months-old toddlers who participated in an earlier study in order…
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- NCT00303316
- Testing
- DTaP-IPV//PRP~T combined vaccine
- Where
- Argentina
- Volunteers
- 458 people, healthy volunteers welcome
- Sponsor
- Sanofi
Sexually Transmitted Infections (Not HIV or Hepatitis), Premature Birth
Genital Tract Infections, the Vaginal Microbiome and Gestational Age at Birth Among Pregnant Women in South Africa
This cohort study plans to investigate associations between the presence of multiple lower genital tract microorganisms in pregnancy and gestational age at birth.
- Conditions
- Sexually Transmitted Infections (Not HIV or Hepatitis), Premature Birth, Pregnancy; Infection, Microbial Colonization
- Trial name
- NCT06131749
- Testing
- No intervention
- Where
- South Africa
- Volunteers
- 603 people
- Sponsor
- University of Bern
Hepatitis C, HCV
Hepatitis C Treatment in Probation and Parole Office
This prospective cohort study compares aims to determine the efficacy and effectiveness of telemedicine-supported on-site linkage to care and treatment in a community probation and parole office (P\&P office) setting and compare…
- Trial name
- NCT05413785
- Testing
- Telehealth in Parole/Probation Office
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Jens Rosenau
Chronic Hepatitis C
A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C
This dose-escalating study is to evaluate the efficacy and the safety of different doses of a new bio-product Pegylated Recombinant Consensus Interferon Variant Solution for Injection (PEG-IFN-SA) and Ribavirin（RBV） in the…
- Trial name
- NCT01908335
- Testing
- PEG-IFN-SA /RBV low dose, PEG-IFN-SA /RBV middle dose, PEG-IFN-SA /RBV high dose
- Where
- 52 sites in China
- Volunteers
- 212 people
- Sponsor
- Beijing Kawin Technology Share-Holding Co., Ltd.
Hepatitis C
Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)
This is a study comparing grazoprevir (MK-5172) plus elbasvir (MK-8742) treatment with sofosbuvir (SOF) plus Pegylated Interferon plus Ribavirin (RBV) [PR] treatment in treatment-naïve and prior PR treatment failure participants…
- Trial name
- NCT02358044
- Testing
- Sofosbuvir, PegIntron, Ribavirin
- Volunteers
- 257 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.